ropinirole and Restless Leg Syndrome studies

Research Excerpts

Excerpt	Relevance	Reference
"As with studies of other dopamine agonists, previously reported studies of ropinirole in restless legs syndrome (RLS) recruited patients with baseline International Restless Legs Scale (IRLS) total scores ≥ 15."	9.17	Ropinirole in patients with restless legs syndrome and baseline IRLS total scores ≥ 24: efficacy and tolerability in a 26-week, double-blind, parallel-group, placebo-controlled study followed by a 40-week open-label extension. ( Asgharian, A; Giorgi, L; Hunter, B, 2013)
"The purpose of this study was to evaluate the incidence of augmentation over 66 weeks of treatment with ropinirole in patients with primary restless legs syndrome (RLS)."	9.16	Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks. ( Allen, R; Asgharian, A; Ferini-Strambi, L; García-Borreguero, D; Hill-Zabala, C; Högl, B; Winkelman, J, 2012)
"Pramipexole and ropinirole have become the first-line treatment for restless legs syndrome."	9.15	Pramipexole versus ropinirole: polysomnographic acute effects in restless legs syndrome. ( Bottasini, V; Ferini-Strambi, L; Ferri, R; Giarolli, L; Manconi, M; Oldani, A; Zucconi, M, 2011)
"To determine whether clinical response to the dopamine agonist, ropinirole, in the treatment of primary restless legs syndrome (RLS), depends upon the age-at-onset of RLS symptoms."	9.13	Clinical efficacy of ropinirole for restless legs syndrome is not affected by age at symptom onset. ( Allen, RP; Ritchie, SY, 2008)
"To assess the long-term safety and efficacy of ropinirole in the treatment of patients with restless legs syndrome (RLS) over 52 weeks."	9.12	A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome. ( Dom, R; Dreykluft, T; Garcia-Borreguero, D; Grunstein, R; Lainey, E; Montagna, P; Moorat, A; Roberts, J; Sridhar, G, 2007)
"The objective of this study was to investigate the long-term efficacy of ropinirole in patients with restless legs syndrome (RLS) and to assess the potential for relapse after the discontinuation of active treatment."	9.12	Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial. ( Haan, J; Karrasch, J; Montplaisir, J; Volc, D, 2006)
"To assess the efficacy, safety, and tolerability of the dopamine agonist ropinirole in the treatment of patients with moderate to severe primary restless legs syndrome (RLS)."	9.12	Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. ( Bogan, RK; Carson, SW; Fry, JM; Ritchie, SY; Schmidt, MH, 2006)
"To assess the efficacy, safety, and tolerability of ropinirole in the treatment of patients with restless legs syndrome."	9.11	Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. ( de Weerd, AW; Ferini-Strambi, L; Garcia-Borreguero, D; Lainey, E; Montagna, P; Saletu-Zyhlarz, G; Telstad, W; Tidswell, P; Trenkwalder, C, 2004)
"Polysomnographic study evaluating the efficacy of ropinirole for the treatment of patients with restless legs syndrome (RLS) suffering from periodic leg movements in sleep (PLMS)."	9.11	Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. ( Allen, R; Becker, PM; Bogan, R; Fry, JM; Kushida, CA; Poceta, JS; Schmidt, M; Winslow, D, 2004)
"Dopaminergic agents such as ropinirole are the drugs of first choice in treating restless legs syndrome (RLS)."	9.10	Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. ( Happe, S; Klösch, G; Saletu, B; Sauter, C; Zeitlhofer, J, 2003)
"We sought to determine whether the non-ergoline dopamine agonist ropinirole is associated with nausea and vomiting in adults with RLS."	8.98	Prevalence of Nausea and Vomiting in Adults Using Ropinirole: A Systematic Review and Meta-Analysis. ( Bielefeldt, K; Kurin, M; Levinthal, DJ, 2018)
"Based on an internal request, GlaxoSmithKline conducted a retrospective pooled analysis of randomized controlled trials to compare suicidality in adult subjects with restless legs syndrome (RLS) who were being treated with ropinirole."	8.91	A Retrospective, Pooled Suicidality Evaluation of Ropinirole Immediate Release and Controlled Release for the Treatment of Restless Legs Syndrome. ( Makumi, CW; Paska, W; Rolfe, K; Shulman, KJ, 2015)
"To compare the effects of ropinirole with those of placebo on sleep, as evaluated by specific domains of the Medical Outcomes Study (MOS) sleep scale, as well as the Clinical Global Impression-Improvement (CGI-I) scale, in patients with restless legs syndrome (RLS)."	8.85	Effect of ropinirole on sleep outcomes in patients with restless legs syndrome: meta-analysis of pooled individual patient data from randomized controlled trials. ( Calloway, MO; Gilsenan, AW; Hansen, RA; Kim, MM; Moore, CG; Murray, MD; Song, L, 2009)
"In the absence of comparative trials a meta-analysis was performed to compare the efficacy and tolerability of the non-ergot derived dopamine agonists, pramipexole and ropinirole, in restless legs syndrome (RLS)."	8.84	Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome. ( Abrams, KR; Finnern, HW; Lleu, PL; Martin, M; Nicolas, A; Petit, C; Quilici, S, 2008)
"In this paper we discuss therapy with ropinirole (known as adartrel in the United Kingdom) in patients with restless legs syndrome."	8.83	Ropinirole treatment for restless legs syndrome. ( Fornadi, K; Molnar, MZ; Shapiro, CM, 2006)
"The objective of this study is to assess adherence and persistence of ropinirole, pramipexole, and gabapentin; to investigate factors associated with non-adherence and non-persistence in restless legs syndrome (RLS) patients."	7.88	Adherence and persistence to ropinirole, pramipexole, and gabapentin in patients with newly diagnosed restless legs syndrome. ( Hartzema, AG; Kim, J, 2018)
"Prospective documentation of pregnancies exposed to levodopa, pramipexole, rotigotine, and ropinirole between 1998 and 2011 was evaluated as to their outcome (teratogenicity or fetotoxicity) by the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy."	7.79	Pregnancy outcome following use of levodopa, pramipexole, ropinirole, and rotigotine for restless legs syndrome during pregnancy: a case series. ( Dostal, M; Schaefer, C; Sobesky, J; Weber-Schoendorfer, C, 2013)
"The aim of the present placebo-controlled sleep laboratory study was to compare the acute effects of gabapentin (GBT) and ropinirole (ROP) in restless legs syndrome (RLS)."	7.76	Comparative placebo-controlled polysomnographic and psychometric studies on the acute effects of gabapentin versus ropinirole in restless legs syndrome. ( Anderer, P; Gruber, G; Nia, S; Parapatics, S; Saletu, B; Saletu, M; Saletu-Zyhlarz, GM, 2010)
"Results from one of the largest clinical trial programmes to date of a dopamine agonist in patients with primary restless legs syndrome (RLS) have demonstrated that ropinirole, 0."	7.73	Efficacy and tolerability of ropinirole in patients with restless legs syndrome and a baseline IRLS total score > or = 24 points--data from the ropinirole clinical trial programme. ( Giorgi, L; Kirsch, JM; Ritchie, SY, 2006)
" Visits were scheduled at screening, baseline, and weeks 1, 4, and 12 with additional telephone contacts for dosing decisions."	6.76	Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomized, placebo-controlled study. ( Banik, N; Benes, H; Bergmann, L; Dreykluft, T; Hansen, C; Hornyak, M; Kohnen, R; Mattern, W; Peglau, I; Schoen, SW, 2011)
"Ropinirole was effective and well tolerated for treating the symptoms of RLS."	6.71	Ropinirole for restless legs syndrome: a placebo-controlled crossover trial. ( Adler, CH; Anderson, WM; Caviness, JN; Hauser, RA; Hentz, JG; Marlor, L; Sethi, K, 2004)
"Ropinirole successfully treated long-standing RLS and can be considered a viable short-term treatment for this condition."	6.71	Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome. ( Bliwise, DL; Chakravorty, S; Freeman, A; Ingram, CD; Rye, DB; Watts, RL, 2005)
"Although the restless legs syndrome (RLS) is a disorder with a relatively high prevalence rate (8% in Austria) and leads to insomnia and excessive daytime tiredness, there is a paucity of sleep laboratory data concerning objective and subjective sleep and awakening quality."	6.69	Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality. ( Brandstätter, N; Gruber, G; Hauer, C; Prause, W; Ritter, K; Saletu, B; Saletu, M; Saletu-Zyhlarz, G, 2000)
"Ropinirole has been studied for treatment of moderate to severe primary RLS in a comprehensive clinical development program."	6.44	Ropinirole treatment for restless legs syndrome. ( Bogan, RK, 2008)
"The symptoms of restless legs syndrome are responsive to dopaminergic agents such as ropinirole."	6.43	Ropinirole in the treatment of restless legs syndrome. ( Kakar, RS; Kushida, CA, 2005)
"Ropinirole is a non-ergoline dopamine agonist that exhibits a high affinity for D(2) and D(3) receptors but little or no affinity for D(1)-like and non-dopaminergic receptors."	6.42	Ropinirole: for the treatment of restless legs syndrome. ( Bang, LM; Cheer, SM; Keating, GM, 2004)
" Data were collected in a retrospective manner from 95 patients who were tracked over the course of their therapy to determine whether psychosis or associated behavioral symptoms developed as a result and whether an intervention was needed to adjust ropinirole dosing or if additional medications had to be added to control features associated with psychosis."	5.35	An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease. ( Carver, LJ; Dahmen, MM; Lea, JW; Makos, M; Rasu, RS; Stoner, SC, 2009)
"Pramipexole extended release could be an easy, safe, and fast pharmacological option to treat augmentation in patients with restless legs syndrome."	5.19	Polysomnographic record and successful management of augmentation in restless legs syndrome/Willis-Ekbom disease. ( Bassetti, CL; Ferini-Strambi, L; Fulda, S; Maestri, M; Manconi, M; Marelli, S; Staedler, C; Zucconi, M, 2014)
"As with studies of other dopamine agonists, previously reported studies of ropinirole in restless legs syndrome (RLS) recruited patients with baseline International Restless Legs Scale (IRLS) total scores ≥ 15."	5.17	Ropinirole in patients with restless legs syndrome and baseline IRLS total scores ≥ 24: efficacy and tolerability in a 26-week, double-blind, parallel-group, placebo-controlled study followed by a 40-week open-label extension. ( Asgharian, A; Giorgi, L; Hunter, B, 2013)
"The purpose of this study was to evaluate the incidence of augmentation over 66 weeks of treatment with ropinirole in patients with primary restless legs syndrome (RLS)."	5.16	Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks. ( Allen, R; Asgharian, A; Ferini-Strambi, L; García-Borreguero, D; Hill-Zabala, C; Högl, B; Winkelman, J, 2012)
"Pramipexole and ropinirole have become the first-line treatment for restless legs syndrome."	5.15	Pramipexole versus ropinirole: polysomnographic acute effects in restless legs syndrome. ( Bottasini, V; Ferini-Strambi, L; Ferri, R; Giarolli, L; Manconi, M; Oldani, A; Zucconi, M, 2011)
"To determine whether clinical response to the dopamine agonist, ropinirole, in the treatment of primary restless legs syndrome (RLS), depends upon the age-at-onset of RLS symptoms."	5.13	Clinical efficacy of ropinirole for restless legs syndrome is not affected by age at symptom onset. ( Allen, RP; Ritchie, SY, 2008)
"The objective of this study was to investigate the long-term efficacy of ropinirole in patients with restless legs syndrome (RLS) and to assess the potential for relapse after the discontinuation of active treatment."	5.12	Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial. ( Haan, J; Karrasch, J; Montplaisir, J; Volc, D, 2006)
"To assess the long-term safety and efficacy of ropinirole in the treatment of patients with restless legs syndrome (RLS) over 52 weeks."	5.12	A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome. ( Dom, R; Dreykluft, T; Garcia-Borreguero, D; Grunstein, R; Lainey, E; Montagna, P; Moorat, A; Roberts, J; Sridhar, G, 2007)
"To assess the efficacy, safety, and tolerability of the dopamine agonist ropinirole in the treatment of patients with moderate to severe primary restless legs syndrome (RLS)."	5.12	Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. ( Bogan, RK; Carson, SW; Fry, JM; Ritchie, SY; Schmidt, MH, 2006)
"Polysomnographic study evaluating the efficacy of ropinirole for the treatment of patients with restless legs syndrome (RLS) suffering from periodic leg movements in sleep (PLMS)."	5.11	Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. ( Allen, R; Becker, PM; Bogan, R; Fry, JM; Kushida, CA; Poceta, JS; Schmidt, M; Winslow, D, 2004)
"To assess the efficacy, safety, and tolerability of ropinirole in the treatment of patients with restless legs syndrome."	5.11	Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. ( de Weerd, AW; Ferini-Strambi, L; Garcia-Borreguero, D; Lainey, E; Montagna, P; Saletu-Zyhlarz, G; Telstad, W; Tidswell, P; Trenkwalder, C, 2004)
"Dopaminergic agents such as ropinirole are the drugs of first choice in treating restless legs syndrome (RLS)."	5.10	Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. ( Happe, S; Klösch, G; Saletu, B; Sauter, C; Zeitlhofer, J, 2003)
"We sought to determine whether the non-ergoline dopamine agonist ropinirole is associated with nausea and vomiting in adults with RLS."	4.98	Prevalence of Nausea and Vomiting in Adults Using Ropinirole: A Systematic Review and Meta-Analysis. ( Bielefeldt, K; Kurin, M; Levinthal, DJ, 2018)
"Based on an internal request, GlaxoSmithKline conducted a retrospective pooled analysis of randomized controlled trials to compare suicidality in adult subjects with restless legs syndrome (RLS) who were being treated with ropinirole."	4.91	A Retrospective, Pooled Suicidality Evaluation of Ropinirole Immediate Release and Controlled Release for the Treatment of Restless Legs Syndrome. ( Makumi, CW; Paska, W; Rolfe, K; Shulman, KJ, 2015)
") and restless legs syndrome treated with ropinirole and gabapentin, will be discussed."	4.89	Recent advances in sleep research. ( Anderer, P; Saletu, B; Saletu-Zyhlarz, GM, 2013)
"To compare the effects of ropinirole with those of placebo on sleep, as evaluated by specific domains of the Medical Outcomes Study (MOS) sleep scale, as well as the Clinical Global Impression-Improvement (CGI-I) scale, in patients with restless legs syndrome (RLS)."	4.85	Effect of ropinirole on sleep outcomes in patients with restless legs syndrome: meta-analysis of pooled individual patient data from randomized controlled trials. ( Calloway, MO; Gilsenan, AW; Hansen, RA; Kim, MM; Moore, CG; Murray, MD; Song, L, 2009)
"Ropinirole hydrochloride (REQUIP, ADARTREL) and pramipexole dihydrochloride (MIRAPEX, SIFROL) are two putative dopamine D(3) receptor subtype-selective agonists recently approved by the FDA for the treatment of 'restless legs syndrome' (RLS)."	4.85	Critical review of ropinirole and pramipexole - putative dopamine D(3)-receptor selective agonists - for the treatment of RLS. ( Ako-Agugua, N; Colasante, J; Hertweck, L; Houser, T; Nagar, S; Raffa, RB; Smith, J; Varga, LI; Watty, AA, 2009)
"In the absence of comparative trials a meta-analysis was performed to compare the efficacy and tolerability of the non-ergot derived dopamine agonists, pramipexole and ropinirole, in restless legs syndrome (RLS)."	4.84	Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome. ( Abrams, KR; Finnern, HW; Lleu, PL; Martin, M; Nicolas, A; Petit, C; Quilici, S, 2008)
"In this paper we discuss therapy with ropinirole (known as adartrel in the United Kingdom) in patients with restless legs syndrome."	4.83	Ropinirole treatment for restless legs syndrome. ( Fornadi, K; Molnar, MZ; Shapiro, CM, 2006)
"To review the use of newer dopamine agonists pramipexole and ropinirole, in the treatment of restless legs syndrome (RLS)."	4.81	Newer dopamine agonists in the treatment of restless legs syndrome. ( Ernst, ME; Weimerskirch, PR, 2001)
"The objective of this study is to assess adherence and persistence of ropinirole, pramipexole, and gabapentin; to investigate factors associated with non-adherence and non-persistence in restless legs syndrome (RLS) patients."	3.88	Adherence and persistence to ropinirole, pramipexole, and gabapentin in patients with newly diagnosed restless legs syndrome. ( Hartzema, AG; Kim, J, 2018)
"Prospective documentation of pregnancies exposed to levodopa, pramipexole, rotigotine, and ropinirole between 1998 and 2011 was evaluated as to their outcome (teratogenicity or fetotoxicity) by the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy."	3.79	Pregnancy outcome following use of levodopa, pramipexole, ropinirole, and rotigotine for restless legs syndrome during pregnancy: a case series. ( Dostal, M; Schaefer, C; Sobesky, J; Weber-Schoendorfer, C, 2013)
" The first patient, a 46-year-old man, was treated with ropinirole for restless legs syndrome and had lost huge amounts of money in the context of internet-based poker game."	3.77	[Pathological gambling induced by dopamine agonists]. ( Connemann, BJ; Gahr, M; Schönfeldt-Lecuona, CJ, 2011)
"The aim of the present placebo-controlled sleep laboratory study was to compare the acute effects of gabapentin (GBT) and ropinirole (ROP) in restless legs syndrome (RLS)."	3.76	Comparative placebo-controlled polysomnographic and psychometric studies on the acute effects of gabapentin versus ropinirole in restless legs syndrome. ( Anderer, P; Gruber, G; Nia, S; Parapatics, S; Saletu, B; Saletu, M; Saletu-Zyhlarz, GM, 2010)
"To estimate the cost-effectiveness of pramipexole versus no treatment and ropinirole in moderate to very severe idiopathic restless legs syndrome (RLS) in the UK and Sweden."	3.74	Cost-effectiveness of licensed treatment options for restless legs syndrome in the UK and Sweden. ( DasGupta, R; Finnern, HW; Lees, M; Roberts, G; Tabberer, M, 2008)
"Restless legs syndrome is a neurological disorder that can be treated with ropinirole."	3.74	Ropinirole-induced symptomatic sinus node dysfunction. ( Boey, S; Hermida, JS; Szymanski, C, 2008)
"Two matching, placebo-controlled, multinational studies assessing the effectiveness and safety of ropinirole for treating moderate-to-severe Restless Legs Syndrome (RLS) formed the basis of this psychometric assessment."	3.73	The reliability, validity and responsiveness of the Restless Legs Syndrome Quality of Life questionnaire (RLSQoL) in a trial population. ( Abetz, L; Allen, RP; Arbuckle, R; Kirsch, J; Mavraki, E, 2005)
"Results from one of the largest clinical trial programmes to date of a dopamine agonist in patients with primary restless legs syndrome (RLS) have demonstrated that ropinirole, 0."	3.73	Efficacy and tolerability of ropinirole in patients with restless legs syndrome and a baseline IRLS total score > or = 24 points--data from the ropinirole clinical trial programme. ( Giorgi, L; Kirsch, JM; Ritchie, SY, 2006)
" Visits were scheduled at screening, baseline, and weeks 1, 4, and 12 with additional telephone contacts for dosing decisions."	2.76	Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomized, placebo-controlled study. ( Banik, N; Benes, H; Bergmann, L; Dreykluft, T; Hansen, C; Hornyak, M; Kohnen, R; Mattern, W; Peglau, I; Schoen, SW, 2011)
"Ropinirole was effective and well tolerated for treating the symptoms of RLS."	2.71	Ropinirole for restless legs syndrome: a placebo-controlled crossover trial. ( Adler, CH; Anderson, WM; Caviness, JN; Hauser, RA; Hentz, JG; Marlor, L; Sethi, K, 2004)
"Ropinirole successfully treated long-standing RLS and can be considered a viable short-term treatment for this condition."	2.71	Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome. ( Bliwise, DL; Chakravorty, S; Freeman, A; Ingram, CD; Rye, DB; Watts, RL, 2005)
"Although the restless legs syndrome (RLS) is a disorder with a relatively high prevalence rate (8% in Austria) and leads to insomnia and excessive daytime tiredness, there is a paucity of sleep laboratory data concerning objective and subjective sleep and awakening quality."	2.69	Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality. ( Brandstätter, N; Gruber, G; Hauer, C; Prause, W; Ritter, K; Saletu, B; Saletu, M; Saletu-Zyhlarz, G, 2000)
"RLS in end-stage renal disease (ESRD) patients is especially problematic due to premature discontinuation of dialysis and increased mortality."	2.55	Clinical management of restless legs syndrome in end-stage renal disease patients. ( Jo, J; Mousa, SA; Sahli, ZT; Tarazi, FI, 2017)
"Treatment of restless legs syndrome (RLS) has as its goals alleviation of the primary symptoms of the disorder and establishment of normal sleep."	2.44	Restless legs syndrome: nonpharmacologic and pharmacologic treatments. ( Allen, RP; Hening, W; Tenzer, P; Winkelman, JW, 2007)
"Ropinirole has been studied for treatment of moderate to severe primary RLS in a comprehensive clinical development program."	2.44	Ropinirole treatment for restless legs syndrome. ( Bogan, RK, 2008)
"The symptoms of restless legs syndrome are responsive to dopaminergic agents such as ropinirole."	2.43	Ropinirole in the treatment of restless legs syndrome. ( Kakar, RS; Kushida, CA, 2005)
"Ropinirole is a non-ergoline dopamine agonist that exhibits a high affinity for D(2) and D(3) receptors but little or no affinity for D(1)-like and non-dopaminergic receptors."	2.42	Ropinirole: for the treatment of restless legs syndrome. ( Bang, LM; Cheer, SM; Keating, GM, 2004)
" It may be related with using a similar dosage of dopaminergic drugs."	1.42	Augmentation in restless legs syndrome patients in Korea. ( Cho, YW; Jeon, JY; Lee, HB; Moon, HJ; Song, ML, 2015)
"These agents are used to treat Parkinson disease, restless leg syndrome, and hyperprolactinemia."	1.40	Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. ( Glenmullen, J; Mattison, DR; Moore, TJ, 2014)
"However, patients with restless legs syndrome, either drug free or taking dopamine agonists, had preferences toward risky choices on the Iowa Gambling Task, which led to negative consequences in the long run, a condition potentially leading to further development of impulse control disorders."	1.39	Decision-making, reward-seeking behaviors and dopamine agonist therapy in restless legs syndrome. ( Bayard, S; Dauvilliers, Y; Langenier, MC, 2013)
"To determine the frequency of impulse control disorders (ICDs) with the use of dopaminergic agents in restless legs syndrome (RLS)."	1.36	Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. ( Cornelius, JR; Frerichs, CF; Silber, MH; Slocumb, NL; Tippmann-Peikert, M, 2010)
"That restless legs can occur simultaneously in a phantom as well as a real limb and that the perception of movement in a phantom limb as well as dopaminergic treatment improved the symptoms provides further support for the important role of central nervous system dysfunction in the development of this disorder."	1.35	Bilateral restless legs affecting a phantom limb, treated with dopamine agonists. ( Drago, V; Foster, PS; Heilman, KM; Skidmore, FM, 2009)
" Data were collected in a retrospective manner from 95 patients who were tracked over the course of their therapy to determine whether psychosis or associated behavioral symptoms developed as a result and whether an intervention was needed to adjust ropinirole dosing or if additional medications had to be added to control features associated with psychosis."	1.35	An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease. ( Carver, LJ; Dahmen, MM; Lea, JW; Makos, M; Rasu, RS; Stoner, SC, 2009)
"She was diagnosed with definite Restless Legs Syndrome (RLS) according to 2003 NIH criteria."	1.35	Effectiveness of ropinirole for RLS and depressive symptoms in an 11-year-old girl. ( Cortese, S; Konofal, E; Lecendreux, M, 2009)
"Ropinirole is a modern dopamine agonist with a half-life of medium extent that is highly selective for D(2)-receptors."	1.33	Clinical studies with ropinirole in Parkinson's disease and RLS. ( Angersbach, D; Jost, WH; Rascol, O, 2006)

Research

Studies (107)

Authors

Clinical Trials (6)

Trial Overview

Trial Outcomes

Mean Change From Baseline in the IRLS Rating Scale Total Score at Week 67

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (1.87)	18.2507
2000's	67 (62.62)	29.6817
2010's	37 (34.58)	24.3611
2020's	1 (0.93)	2.80

Authors	Studies
Neo, S	1
Xu, Z	1
Kurin, M	1
Bielefeldt, K	1
Levinthal, DJ	1
Sinclair, PM	1
Kim, J	1
Hartzema, AG	1
Wang, A	1
Foster, K	1
Skeba, P	1
Hiranniramol, K	1
Earley, CJ	1
Allen, RP	6
Fowler, E	1
Maderal, A	1
Yosipovitch, G	1
Launois, C	1
Leu-Semenescu, S	1
Brion, A	1
Arnulf, I	3
Giorgi, L	2
Asgharian, A	2
Hunter, B	1
Bayard, S	1
Langenier, MC	1
Dauvilliers, Y	1
Amos, LB	1
Grekowicz, ML	1
Kuhn, EM	1
Olstad, JD	1
Collins, MM	1
Norins, NA	1
D'Andrea, LA	1
Snider, S	1
Saletu, B	5
Anderer, P	3
Saletu-Zyhlarz, GM	2
Maestri, M	1
Fulda, S	1
Ferini-Strambi, L	5
Zucconi, M	2
Marelli, S	1
Staedler, C	1
Bassetti, CL	2
Manconi, M	2
Sun, Y	1
van Valkenhoef, G	1
Morel, T	1
Jeon, JY	1
Moon, HJ	1
Song, ML	1
Lee, HB	1
Cho, YW	1
Moore, TJ	1
Glenmullen, J	1
Mattison, DR	1
Makumi, CW	1
Paska, W	1
Rolfe, K	1
Shulman, KJ	1
Wijemanne, S	1
Jankovic, J	1
Chokroverty, S	1
Kuhn, PJ	1
Olson, DJ	1
Sullivan, JP	1
Sahli, ZT	1
Jo, J	1
Mousa, SA	1
Tarazi, FI	1
Winkelman, JW	2
Mackie, SE	1
Mei, LA	1
Platt, S	1
Schoerning, L	1
Gopaluni, S	1
Sherif, M	1
Ahmadouk, NA	1
Thomas, K	1
Watson, CB	1
Morgan, JC	1
Ames, M	1
Sethi, KD	1
Szymanski, C	1
Boey, S	1
Hermida, JS	1
Juergens, TM	1
Lees, M	1
Roberts, G	1
Tabberer, M	1
DasGupta, R	1
Finnern, HW	2
Kosinski, M	1
Hill-Zabala, CE	1
Calloway, MO	3
Evans, AH	1
Stegeman, JR	1
Urbano, MR	1
Ware, JC	1
Fine, IH	1
Dworetzky, J	1
Hoffman, RS	1
Packer, M	1
Rose, AR	1
Antic, NA	1
McEvoy, RD	1
Léger, D	1
Ogrizek, P	1
Valko, PO	1
Siccoli, MM	1
Weber, WE	1
Nijssen, PC	1
Hansen, RA	1
Song, L	1
Moore, CG	1
Gilsenan, AW	1
Kim, MM	1
Murray, MD	1
Skidmore, FM	1
Drago, V	1
Foster, PS	1
Heilman, KM	1
Nelles, S	1
Köberlein, J	1
Grimm, C	1
Pittrow, D	1
Kirch, W	1
Rychlik, R	1
Stoner, SC	1
Dahmen, MM	1
Makos, M	1
Lea, JW	1
Carver, LJ	1
Rasu, RS	1
Kim, HJ	1
Park, SY	1
Cho, YJ	1
Hong, KS	1
Cho, JY	1
Seo, SY	1
Lee, DH	1
Jeon, BS	1
Varga, LI	1
Ako-Agugua, N	1
Colasante, J	1
Hertweck, L	1
Houser, T	1
Smith, J	1
Watty, AA	1
Nagar, S	1
Raffa, RB	1
Saletu, M	3
Parapatics, S	1
Gruber, G	2
Nia, S	1
Cornelius, JR	1
Tippmann-Peikert, M	1
Slocumb, NL	1
Frerichs, CF	1
Silber, MH	2
Benes, H	1
Mattern, W	1
Peglau, I	1
Dreykluft, T	3
Bergmann, L	1
Hansen, C	1
Kohnen, R	1
Banik, N	1
Schoen, SW	1
Hornyak, M	2
Navacerrada, F	1
González-Alonso, MR	1
Alonso-Navarro, H	1
Pilo-de-la-Fuente, B	1
Plaza-Nieto, JF	1
Jiménez-Jiménez, FJ	1
Ferri, R	1
Oldani, A	1
Giarolli, L	1
Bottasini, V	1
Ondo, WG	3
Ball, E	2
Manjunath, R	1
Higbie, RL	1
Lee, MR	1
Nisbet, PA	1
Cripps, MG	1
Gahr, M	1
Connemann, BJ	1
Schönfeldt-Lecuona, CJ	1
Tzonova, D	1
Larrosa, O	1
Calvo, E	1
Granizo, JJ	1
Williams, AM	1
de la Llave, Y	1
García-Borreguero, D	4
Högl, B	1
Winkelman, J	1
Hill-Zabala, C	1
Allen, R	2
Jones, HB	1
George, S	1
Dorfman, BJ	1
Nirenberg, MJ	1
de Biase, S	1
Merlino, G	1
Lorenzut, S	1
Valente, M	1
Gigli, GL	1
Aurora, RN	1
Kristo, DA	1
Bista, SR	1
Rowley, JA	1
Zak, RS	1
Casey, KR	1
Lamm, CI	1
Tracy, SL	1
Rosenberg, RS	1
Dostal, M	1
Weber-Schoendorfer, C	1
Sobesky, J	1
Schaefer, C	1
Happe, S	1
Sauter, C	1
Klösch, G	1
Zeitlhofer, J	1
Trenkwalder, C	2
Montagna, P	2
Lainey, E	2
de Weerd, AW	1
Tidswell, P	1
Saletu-Zyhlarz, G	3
Telstad, W	1
Adler, CH	1
Hauser, RA	1
Sethi, K	2
Caviness, JN	1
Marlor, L	1
Anderson, WM	1
Hentz, JG	1
Konofal, E	3
Gauthier, C	1
Chedru, F	1
Walther, BW	1
Cheer, SM	1
Bang, LM	1
Keating, GM	1
Walters, AS	1
Grunstein, R	2
Lee, D	1
Becker, PM	1
Bogan, R	1
Schmidt, M	1
Kushida, CA	2
Fry, JM	2
Poceta, JS	1
Winslow, D	1
Bliwise, DL	1
Freeman, A	1
Ingram, CD	1
Rye, DB	1
Chakravorty, S	1
Watts, RL	1
Thorpy, M	1
Plowman, BK	1
Boggie, DT	1
Morreale, AP	1
Schaefer, MG	1
Delattre, ML	1
Chan, H	1
Kinge, E	1
Lossius, MI	1
Mowincel, P	1
Kakar, RS	1
Lecendreux, M	2
Mouren, MC	1
Hellebek, A	1
Kampmann, JP	1
Abetz, L	1
Arbuckle, R	1
Mavraki, E	1
Kirsch, J	1
Bogan, RK	2
Schmidt, MH	1
Carson, SW	1
Ritchie, SY	3
Perea, E	1
Robbins, BV	1
Hutto, B	1
Woloshin, S	1
Schwartz, LM	1
Montplaisir, J	1
Karrasch, J	1
Haan, J	1
Volc, D	1
Dyer, O	1
Jost, WH	1
Angersbach, D	1
Rascol, O	1
Kirsch, JM	1
Molnar, MZ	1
Fornadi, K	1
Shapiro, CM	1
Dobson, AM	1
Cuellar, N	1
Obah, C	1
Fine, PG	1
Qu, S	1
Le, W	1
Zhang, X	1
Xie, W	1
Zhang, A	1
Sridhar, G	1
Dom, R	1
Moorat, A	1
Roberts, J	1
Tenzer, P	1
Hening, W	1
Spiegelhalder, K	1
Quilici, S	1
Abrams, KR	1
Nicolas, A	1
Martin, M	1
Petit, C	1
Lleu, PL	1
Cortese, S	1
Molokwu, OC	1
Caivano, CK	1
Chitnis, S	1
Ondo, W	1
Gálvez-Jiménez, N	1
Khan, T	1
Brandstätter, N	1
Hauer, C	2
Prause, W	1
Ritter, K	1
Mandl, M	1
Oberndorfer, S	1
Zoghlami, A	1
Weimerskirch, PR	1
Ernst, ME	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Effect of Magnesium Citrate Supplementation in Patients With Restless Legs Syndrome (RLS) - An Open Label, Prospective, Non Placebo Controlled Pilot Study[NCT04462796]		15 participants (Anticipated)	Interventional	2020-07-10	Recruiting
A Parallel Group Study to Evaluate the Efficacy and Safety of Ropinirole for 26 Weeks and to Further Evaluate the Incidence of Augmentation and Rebound for a Further 40 Weeks Open-label Extension Treatment Period in Subjects Suffering From Moderate to Sev[NCT00329602]	Phase 4	404 participants (Actual)	Interventional	2006-03-31	Completed
The Treatment of Sleep Bruxism With the Luco Hybrid OSA Appliance[NCT02882880]		51 participants (Actual)	Interventional	2015-07-31	Completed
Efficacy and Safety of the RESTIFFIC™ Brand Pressure Application System, the Restless Leg Relaxer to Reduce the Symptoms of Moderate to Severe Restless Leg Syndrome[NCT02386423]		30 participants (Actual)	Interventional	2009-04-30	Completed
Acute Effects of Gabapentin on Polysomnography Parameters and on Hypothalamic-pituitary-adrenal, Hypothalamic-pituitary-gonadal and Somatotropic Axes During Sleep in Older Men: a Randomized, Double-blind, Placebo-controlled Trial[NCT02599701]	Phase 4	8 participants (Actual)	Interventional	2015-09-30	Terminated (stopped due to Gabapentin increased hypopnea-apnea index in the first 8 recruited subjects.)
Heart Rate Variability Assessment in Dialysis Patients by Acupuncture[NCT04356794]		61 participants (Actual)	Interventional	2019-08-23	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

A 10-item, participant-reported scale covering different symptoms of the condition. Each item is scored from 0 to 4, with 0 representing the absence of a problem and 4 reflecting a very severe problem. The best and worst possible scores are 0 and 40, respectively. The primary assessment was made by calculating the difference in the average score obtained at Baseline with score at Week 67. (NCT00329602)
Timeframe: Baseline and Week 67

Median Time to First CGI-I Response of Much/Very Much Improved During the Double-blind Phase

Intervention	points on a scale (Mean)
Open-label Ropinirole IR	-20.4

The median time to first CGI-I response of much/very much improved was calculated. The CGI-I is a psychometric instrument that is used to measure general clinical status in a variety of disease states. The CGI-I allows the investigator to rate the participant's global improvement or worsening compared with the condition at Baseline (Day 0). The scale is rated from 1-7 (1 = very much improved; 7 = very much worse). Typically, a participant with a score of 1 or 2 (much improved) is considered a responder. (NCT00329602)
Timeframe: Baseline to Week 26

Number of Participants Rated as Normal or Borderline Ill on the CGI Severity of Illness (CGI-S) Scale at Week 26

Intervention	days (Median)
Double-blind Placebo	28
Double-blind Ropinirole IR	21

The CGI-S scale is a psychometric instrument that is used to measure general clinical status in a variety of disease states. The CGI-S allows the investigator to rate the severity of the participant's illness considering their total clinical experience with the subject population being studied and on all information available at the time of rating. The scale is rated from 1-7 (1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severly ill; 7 = among the most extremely ill participants). (NCT00329602)
Timeframe: Week 26

Number of Participants With a Score of Much/Very Much Improved on the CGI-I Scale at Week 67

Intervention	participants (Number)
Double-blind Placebo	50
Double-blind Ropinirole IR	50

The CGI-I is a psychometric instrument that is used to measure general clinical status in a variety of disease states. The CGI-I allows the investigator to rate the participant's global improvement or worsening compared with the condition at Baseline (Day 0). The scale is rated from 1-7 (1 = very much improved; 7 = very much worse). Typically, a participant with a score of 1 or 2 (much improved) is considered a responder. (NCT00329602)
Timeframe: Week 67

Number of Participants Withdrawing Due to Lack of Efficacy During the First 26 Weeks of the Study

Intervention	participants (Number)
Open-label Ropinirole IR	184

Lack of efficacy is defined as up to a 10% improvement in the IRLS Rating Scale total score from the participant's Baseline value and at least 12 weeks of treatment during the double-blind phase. (NCT00329602)
Timeframe: Baseline to Week 26

Change From Baseline in Sleep Quantity, a Domain of the 12-item Medical Outcomes Study (MOS-12) Sleep Scale, at Weeks 12 and 26

Intervention	participants (Number)
Double-blind Placebo	2
Double-blind Ropinirole IR	3

The MOS-12 Sleep Scale is a comprehensive battery, which measures specific aspects of sleep in participants that may have varying co-morbidities, and, as a result, is appropriate for a medically diverse participant population.Scores were adjusted for baseline MOS sleep scale domain value, treatment group, visit, visit by treatment interaction, and center group. (NCT00329602)
Timeframe: Baseline and Weeks 12 and 26

Change From Baseline in the Domains of the 12-item Medical Outcomes Study (MOS-12) Sleep Scale at Weeks 12 and 26

Intervention	hours (Least Squares Mean)
	Week 12, n=153, 143	Week 26, n=105, 97
Double-blind Placebo	0.5	0.5
Double-blind Ropinirole IR	0.7	0.7

The MOS-12 Sleep Scale is a comprehensive battery, which measures specific aspects of sleep in participants that may have varying co-morbidities, and, as a result, is appropriate for a medically diverse participant population. Domain values are presented on a 0-100 scale, where a higher score means a greater degree of the attribute implied by the scale name. Scores were adjusted for baseline MOS sleep scale domain value, treatment group, visit, visit by treatment interaction, and center group. (NCT00329602)
Timeframe: Baseline and Weeks 12 and 26

Change From Baseline in the Domains of the MOS 36-item Short Form Health Survey (SF-36) at Weeks 12 and 26

Intervention	points on a scale (Least Squares Mean)
	Sleep disturbance, Week 12, n=153, 143	Sleep disturbance, Week 26, n=105, 97	Sleep adequacy, Week 12, n=153, 143	Sleep adequacy, Week 26, n=105, 97	Daytime somnolence, Week 12, n=153, 143	Daytime somnolence, Week 26, n=105, 97
Double-blind Placebo	-15.0	-16.4	15.0	14.9	-7.5	-9.1
Double-blind Ropinirole IR	-24.0	-24.6	22.8	26.0	-11.4	-11.4

The MOS SF-36 is a generic QoL instrument measuring functional status and well-being. Positive change from baseline for all domains indicates improvement. For all MOS SF-36 domains, the minimum and maximum scores are 0 and 100, respectively, for the transformed scale. Scores were adjusted for baseline domain score, treatment group, visit, visit by treatment interaction, and center group. (NCT00329602)
Timeframe: Baseline and Weeks 12 and 26

Change From Baseline in the Johns Hopkins RLS Quality of Life (RLS QoL) Questionnaire Overall Life Impact Score at Weeks 12 and 26

Intervention	points on a scale (Least Squares Mean)
	Bodily pain, Week 12, n=149, 142	Bodily pain, Week 26, n=104, 94	General health, Week 12, n=149, 142	General health, Week 26, n=104, 94	Mental health, Week 12, n=149, 142	Mental health, Week 26, n=104, 94	Physical functioning, Week 12, n=149, 142	Physical functioning, Week 26, n=104, 94	Role emotional, Week 12, n=149, 142	Role emotional, Week 26, n=104, 94	Role physical, Week 12, n=149, 142	Role physical, Week 26, n=104, 94	Social functioning, Week 12, n=149, 142	Social functioning, Week 26, n=104, 94	Vitality, Week 12, n=149, 142	Vitality, Week 26, n=104, 94
Double-blind Placebo	12.3	13.3	3.0	2.6	5.0	4.6	2.4	3.5	5.1	5.9	5.2	7.5	6.3	7.1	8.0	6.0
Double-blind Ropinirole IR	14.4	14.0	4.5	4.1	7.6	6.2	5.5	2.6	7.0	6.6	7.7	6.7	9.8	8.8	9.3	9.2

The Johns Hopkins RLS QoL Questionnaire is a disease-specific instrument that assesses the impact of RLS on the daily life, emotional well-being, social life, and work life of participants. The overall life impact score for the John Hopkins RLS QoL scale ranges from a lowest possible score of 0 to a highest possible score of 100. Higher scores represent better quality of life. Scores were adjusted for baseline RLS Quality of Life score, treatment group, visit, visit by treatment interaction, and center group. (NCT00329602)
Timeframe: Baseline and Weeks 12 and 26

Mean Change From Baseline in the International Restless Legs Syndrome (IRLS) Rating Scale Total Score at Week 12 and Week 26

Intervention	points on a scale (Least Squares Mean)
	Week 12, n=149, 141	Week 26, n=103, 94
Double-blind Placebo	14.0	16.5
Double-blind Ropinirole IR	18.0	18.5

A 10-item, participant-reported scale covering different symptoms of the condition. Each item is scored from 0 to 4; 0 represents the absence of a problem and 4 reflects a very severe problem. The best and worst possible scores are 0 and 40, respectively; higher scores represent a greater severity of symptoms. A negative change from baseline indicates improvement, and a negative treatment difference indicates a benefit of Ropinirole IR over placebo. The primary assessment was made by calculating the difference in the average score obtained at Baseline with scores at Week 12 and then Week 26. (NCT00329602)
Timeframe: Baseline and Weeks 12 and 26

Mean Change From Baseline in the International RLS (IRLS) Rating Scale Total Score at Weeks 1, 4, 8, 16, and 20

Intervention	points on a scale (Least Squares Mean)
	Week 12, n=165, 164	Week 26, n=119, 123
Double-blind Placebo	-12.1	-13.4
Double-blind Ropinirole IR	-14.2	-15.9

A 10-item, participant-reported scale covering different RLS symptoms. Each item is scored from 0 to 4; 0 represents the absence of a problem and 4 reflects a very severe problem. The best and worst possible scores are 0 and 40, respectively; higher scores represent a greater severity of symptoms. The primary assessment from this study was made by calculating the difference in the average score obtained at Baseline with scores at Weeks 1, 4, 8, 16, and 20. Scores were adjusted for baseline IRLS total score, treatment group, visit, visit by treatment group interaction, and center group. (NCT00329602)
Timeframe: Baseline and Weeks 1, 4, 8, 16, and 20

Number of Participants With Clinically Meaningful Augmentation and Early Morning Rebound (EMR) Cases

Intervention	points on a scale (Least Squares Mean)
	Week 1, n=198, 194	Week 4, n=183, 180	Week 8, n=168, 170	Week 16, n=137, 144	Week 20, n=125, 132
Double-blind Placebo	-5.5	-10.5	-13.0	-12.6	-12.3
Double-blind Ropinirole IR	-7.8	-13.6	-15.3	-15.0	-15.7

Clinically meaningful augmentation and early morning rebound (EMR) were assessed and confirmed by an independent Adjudication Board. EMR describes the development of RLS symptoms during the early morning, following therapeutic intervention. EMR is differentiated from augmentation, in which the earlier onset of symptoms occurs in the evening. (NCT00329602)
Timeframe: During 15-month study duration at scheduled (Weeks 16, 20, 26, or early withdrawal for DB phase; Weeks 39, 47, 55, 63, 67, or early withdrawal for the OL phase) and unscheduled (26-week DB phase and 40-week OL phase) visits

Percentage of Participants With a Score of Much/Very Much Improved on the Clinical Global Impression-Global Improvement (CGI-I) Scale at Weeks 1, 12 and 26

Intervention	participants (Number)
	Confirmed augmentation	Clinically meaningful augmentation	Confirmed EMR
Double-blind Placebo	1	1	1
Double-blind Ropinirole IR	7	5	4
Open-label Ropinirole IR	8	5	2
Overall Study	15	11	7

Post-hoc Analysis of Mean Change From Baseline in the International Restless Legs Syndrome (IRLS) Rating Scale Total Score at Week 12 and Week 26, Exploring the Impact of Center Group on Treatment Effect

Intervention	percentage of participants (Number)
	Week 1, n=192, 192	Week 12, n=165, 160	Week 26, n=112, 108
Double-blind Placebo	39	86	72
Double-blind Ropinirole IR	50	109	91

A post-hoc analysis of the primary outcome measure, exploring the variation in treatment effects across center groups by excluding those with the most extreme treatment effects, was conducted. Centers were grouped into five center groups. (NCT00329602)
Timeframe: Baseline and Weeks 12 and 26

Post-hoc Analysis of Percentage of Participants With a Score of Much/Very Much Improved on the Clinical Global Impression-Global Improvement (CGI-I) Scale at Weeks 12 and 26, Exploring the Impact of Center Group on Treatment Effect

Intervention	Points on a scale (Least Squares Mean)
	Week 12, n=136, 134	Week 26, n=103, 105
Double-blind Placebo	-12.2	-14.0
Double-blind Ropinirole IR	-13.8	-15.7

A post-hoc analysis of CGI-I, exploring the variation in treatment effects across center groups by excluding the same two center groups as in the IRLS post-hoc analysis, was conducted. Centers were grouped into five center groups. (NCT00329602)
Timeframe: Weeks 12 and 26

Article	Year
Prevalence of Nausea and Vomiting in Adults Using Ropinirole: A Systematic Review and Meta-Analysis. Digestive diseases and sciences, 2018, Volume: 63, Issue:3 Topics: Dopamine Agonists; Humans; Indoles; Nausea; Prevalence; Restless Legs Syndrome; Vomiting	2018
Interventions for chronic kidney disease-associated restless legs syndrome. International journal of evidence-based healthcare, 2018, Volume: 16, Issue:3 Topics: Exercise Therapy; Gabapentin; Humans; Indoles; Iron-Dextran Complex; Levodopa; Randomized Controlled	2018
The impact of restless legs syndrome: a familial case study. The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses, 2013, Volume: 45, Issue:6 Topics: Adult; Analgesics, Opioid; Anticonvulsants; Benzodiazepines; Benzothiazoles; Carbidopa; Dopamine Ago	2013
Recent advances in sleep research. Psychiatria Danubina, 2013, Volume: 25, Issue:4 Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Amines; Antiparkinson Agents; Biomedical Research;	2013
A Retrospective, Pooled Suicidality Evaluation of Ropinirole Immediate Release and Controlled Release for the Treatment of Restless Legs Syndrome. Clinical therapeutics, 2015, May-01, Volume: 37, Issue:5 Topics: Adult; Delayed-Action Preparations; Dopamine Agonists; Double-Blind Method; Female; Humans; Indoles;	2015
Restless legs syndrome: clinical presentation diagnosis and treatment. Sleep medicine, 2015, Volume: 16, Issue:6 Topics: Amines; Analgesics, Opioid; Benzothiazoles; Cyclohexanecarboxylic Acids; Dopamine Agonists; Gabapent	2015
Clinical management of restless legs syndrome in end-stage renal disease patients. CNS spectrums, 2017, Volume: 22, Issue:1 Topics: Amines; Analgesics, Opioid; Benzodiazepines; Benzothiazoles; Comorbidity; Cyclohexanecarboxylic Acid	2017
Interventions for chronic kidney disease-associated restless legs syndrome. The Cochrane database of systematic reviews, 2016, 11-07, Volume: 11 Topics: Amines; Anticonvulsants; Ascorbic Acid; Cyclohexanecarboxylic Acids; Dopamine Agonists; Exercise The	2016
Restless legs syndrome in women: a review. Journal of women's health (2002), 2008, Volume: 17, Issue:5 Topics: Benzothiazoles; Diagnosis, Differential; Dopamine Agonists; Female; Humans; Indoles; Life Style; Pra	2008
[Sleep disorders in adults]. La Revue du praticien, 2008, Oct-31, Volume: 58, Issue:16 Topics: Adult; Benzodiazepines; Diagnosis, Differential; Disorders of Excessive Somnolence; Dopamine Agonist	2008
Effect of ropinirole on sleep outcomes in patients with restless legs syndrome: meta-analysis of pooled individual patient data from randomized controlled trials. Pharmacotherapy, 2009, Volume: 29, Issue:3 Topics: Adult; Aged; Dopamine Agonists; Double-Blind Method; Female; Humans; Indoles; Male; Middle Aged; Ran	2009
Treatment options for restless legs syndrome. Expert opinion on pharmacotherapy, 2009, Volume: 10, Issue:4 Topics: Benzothiazoles; Dopamine Agonists; Humans; Indoles; Levodopa; Pramipexole; Restless Legs Syndrome	2009
Critical review of ropinirole and pramipexole - putative dopamine D(3)-receptor selective agonists - for the treatment of RLS. Journal of clinical pharmacy and therapeutics, 2009, Volume: 34, Issue:5 Topics: Animals; Benzothiazoles; Clinical Trials as Topic; Diagnosis, Differential; Dopamine; Dopamine Agoni	2009
ADMET considerations for restless leg syndrome drug treatments. Expert opinion on drug metabolism & toxicology, 2012, Volume: 8, Issue:10 Topics: Amines; Anticonvulsants; Benzothiazoles; Carbamates; Cyclohexanecarboxylic Acids; Dopamine Agents; D	2012
The treatment of restless legs syndrome and periodic limb movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. Sleep, 2012, Aug-01, Volume: 35, Issue:8 Topics: Academies and Institutes; Benzothiazoles; Cabergoline; Carbamates; Dopamine Agents; Ergolines; Evide	2012
Ropinirole: for the treatment of restless legs syndrome. CNS drugs, 2004, Volume: 18, Issue:11 Topics: Antiparkinson Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administratio	2004
Sleep attacks in patients receiving dopamine-receptor agonists. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2005, Mar-01, Volume: 62, Issue:5 Topics: Aged; Benzothiazoles; Dopamine Agonists; Female; Humans; Indoles; Male; Middle Aged; Narcolepsy; Par	2005
Ropinirole in the treatment of restless legs syndrome. Expert review of neurotherapeutics, 2005, Volume: 5, Issue:1 Topics: Dopamine Agonists; Enzyme Inhibitors; Expert Testimony; Humans; Indoles; Levodopa; Restless Legs Syn	2005
Ropinirole (Requip) for restless legs syndrome. Obstetrics and gynecology, 2006, Volume: 107, Issue:1 Topics: Adult; Aged; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug	2006
Giving legs to restless legs: a case study of how the media helps make people sick. PLoS medicine, 2006, Volume: 3, Issue:4 Topics: Deception; Dopamine Agonists; Drug Industry; Humans; Indoles; Journalism, Medical; Mass Media; Preva	2006
The weight of evidence for ropinirole in restless legs syndrome. European journal of neurology, 2006, Volume: 13 Suppl 3 Topics: Dopamine Agonists; Humans; Indoles; Randomized Controlled Trials as Topic; Restless Legs Syndrome	2006
Ropinirole treatment for restless legs syndrome. Drugs of today (Barcelona, Spain : 1998), 2006, Volume: 42, Issue:9 Topics: Adult; Aged; Dopamine Agonists; Female; Humans; Indoles; Male; Middle Aged; Randomized Controlled Tr	2006
Use of ropinirole in RLS. The Nurse practitioner, 2006, Volume: 31, Issue:12 Topics: Algorithms; Dopamine Agonists; Drug Administration Schedule; Drug Monitoring; Humans; Indoles; Patie	2006
Restless legs syndrome: an update on diagnosis and management. Journal of pain & palliative care pharmacotherapy, 2006, Volume: 20, Issue:4 Topics: Aged; Comorbidity; Dopamine Agonists; Female; Humans; Indoles; Male; Restless Legs Syndrome; Sleep D	2006
Restless legs syndrome: nonpharmacologic and pharmacologic treatments. Geriatrics, 2007, Volume: 62, Issue:10 Topics: Amines; Anemia, Iron-Deficiency; Anticonvulsants; Benzothiazoles; Clonazepam; Cyclohexanecarboxylic	2007
Restless legs syndrome in older adults. Clinics in geriatric medicine, 2008, Volume: 24, Issue:1 Topics: Aged, 80 and over; Benzothiazoles; Cabergoline; Circadian Rhythm; Cognition Disorders; Comorbidity;	2008
Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome. Sleep medicine, 2008, Volume: 9, Issue:7 Topics: Benzothiazoles; Dopamine Agonists; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles;	2008
Ropinirole treatment for restless legs syndrome. Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:4 Topics: Dopamine Agonists; Evidence-Based Medicine; Humans; Indoles; Motor Activity; Restless Legs Syndrome;	2008
Internal medicine: guidance to the diagnosis and management of restless legs syndrome. Southern medical journal, 2008, Volume: 101, Issue:6 Topics: Benzothiazoles; Critical Pathways; Cross-Sectional Studies; Dopamine Agonists; Humans; Indoles; Inte	2008
Ropinirole treatment for restless legs syndrome. Expert opinion on drug metabolism & toxicology, 2008, Volume: 4, Issue:5 Topics: Clinical Trials as Topic; Dopamine Agonists; Humans; Indoles; Randomized Controlled Trials as Topic;	2008
Newer dopamine agonists in the treatment of restless legs syndrome. The Annals of pharmacotherapy, 2001, Volume: 35, Issue:5 Topics: Benzothiazoles; Clinical Trials as Topic; Dopamine Agonists; Female; Humans; Indoles; Male; Pramipex	2001

Article	Year
Ropinirole in patients with restless legs syndrome and baseline IRLS total scores ≥ 24: efficacy and tolerability in a 26-week, double-blind, parallel-group, placebo-controlled study followed by a 40-week open-label extension. Clinical therapeutics, 2013, Volume: 35, Issue:9 Topics: Adolescent; Adult; Aged; Dopamine Agonists; Double-Blind Method; European Union; Female; Follow-Up S	2013
Ropinirole in patients with restless legs syndrome and baseline IRLS total scores ≥ 24: efficacy and tolerability in a 26-week, double-blind, parallel-group, placebo-controlled study followed by a 40-week open-label extension. Clinical therapeutics, 2013, Volume: 35, Issue:9 Topics: Adolescent; Adult; Aged; Dopamine Agonists; Double-Blind Method; European Union; Female; Follow-Up S	2013
Ropinirole in patients with restless legs syndrome and baseline IRLS total scores ≥ 24: efficacy and tolerability in a 26-week, double-blind, parallel-group, placebo-controlled study followed by a 40-week open-label extension. Clinical therapeutics, 2013, Volume: 35, Issue:9 Topics: Adolescent; Adult; Aged; Dopamine Agonists; Double-Blind Method; European Union; Female; Follow-Up S	2013
Ropinirole in patients with restless legs syndrome and baseline IRLS total scores ≥ 24: efficacy and tolerability in a 26-week, double-blind, parallel-group, placebo-controlled study followed by a 40-week open-label extension. Clinical therapeutics, 2013, Volume: 35, Issue:9 Topics: Adolescent; Adult; Aged; Dopamine Agonists; Double-Blind Method; European Union; Female; Follow-Up S	2013
Polysomnographic record and successful management of augmentation in restless legs syndrome/Willis-Ekbom disease. Sleep medicine, 2014, Volume: 15, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Benzothiazoles; Delayed-Action Preparations; Dopamine Agonists; Fema	2014
Targeted Pressure on Abductor Hallucis and Flexor Hallucis Brevis Muscles to Manage Moderate to Severe Primary Restless Legs Syndrome. The Journal of the American Osteopathic Association, 2016, Jul-01, Volume: 116, Issue:7 Topics: Adult; Aged; Dopamine Agonists; Drug Tolerance; Female; Foot; Humans; Indoles; Male; Meta-Analysis a	2016
Psychometric evaluation and tests of validity of the Medical Outcomes Study 12-item Sleep Scale (MOS sleep). Sleep medicine, 2009, Volume: 10, Issue:5 Topics: Adolescent; Adult; Aged; Cohort Studies; Dopamine Agonists; Humans; Indoles; Middle Aged; Outcome As	2009
Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomized, placebo-controlled study. Journal of neurology, 2011, Volume: 258, Issue:6 Topics: Aged; Analysis of Variance; Depressive Disorder; Dopamine Agonists; Double-Blind Method; Female; Fol	2011
Pramipexole versus ropinirole: polysomnographic acute effects in restless legs syndrome. Movement disorders : official journal of the Movement Disorder Society, 2011, Volume: 26, Issue:5 Topics: Adult; Aged; Analysis of Variance; Antiparkinson Agents; Benzothiazoles; Double-Blind Method; Female	2011
Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks. Movement disorders : official journal of the Movement Disorder Society, 2012, Volume: 27, Issue:2 Topics: Adult; Aged; Antiparkinson Agents; Double-Blind Method; Female; Follow-Up Studies; Humans; Indoles;	2012
Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. Neuropsychobiology, 2003, Volume: 48, Issue:2 Topics: Acetates; Adult; Aged; Amines; Calcium Channel Blockers; Cross-Over Studies; Cyclohexanecarboxylic A	2003
Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. Journal of neurology, neurosurgery, and psychiatry, 2004, Volume: 75, Issue:1 Topics: Adult; Aged; Dopamine Agonists; Double-Blind Method; Female; Headache; Humans; Indoles; Male; Middle	2004
Ropinirole for restless legs syndrome: a placebo-controlled crossover trial. Neurology, 2004, Apr-27, Volume: 62, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Cross-Over Studies; Dizziness; Dopamine Agonists; Dose-Response Rela	2004
Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:12 Topics: Adolescent; Adult; Aged; Dopamine Agents; Double-Blind Method; Female; Humans; Indoles; Male; Middle	2004
Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep, 2004, Aug-01, Volume: 27, Issue:5 Topics: Antiparkinson Agents; Dopamine Agonists; Double-Blind Method; Female; Humans; Indoles; Male; Middle	2004
Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome. Sleep medicine, 2005, Volume: 6, Issue:2 Topics: Adult; Dopamine Agonists; Double-Blind Method; Female; Humans; Indoles; International Cooperation; M	2005
Ropinirole in the treatment of restless legs syndrome. Current neurology and neuroscience reports, 2005, Volume: 5, Issue:2 Topics: Adolescent; Adult; Aged; Double-Blind Method; Humans; Indoles; Middle Aged; Restless Legs Syndrome	2005
Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clinic proceedings, 2006, Volume: 81, Issue:1 Topics: Adolescent; Adult; Aged; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; F	2006
Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial. Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:10 Topics: Adolescent; Adult; Aged; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Drug-Rel	2006
A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome. Sleep medicine, 2007, Volume: 8, Issue:7-8 Topics: Adult; Aged; Aged, 80 and over; Dopamine Agonists; Female; Humans; Indoles; Male; Middle Aged; Quali	2007
Clinical efficacy of ropinirole for restless legs syndrome is not affected by age at symptom onset. Sleep medicine, 2008, Volume: 9, Issue:8 Topics: Adolescent; Adult; Age Factors; Age of Onset; Aged; Child; Child, Preschool; Dopamine Agonists; Doub	2008
Ropinirole and restless legs syndrome. Movement disorders : official journal of the Movement Disorder Society, 1999, Volume: 14, Issue:5 Topics: Aged; Dopamine Agonists; Female; Follow-Up Studies; Humans; Indoles; Male; Middle Aged; Prospective	1999
Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality. Neuropsychobiology, 2000, Volume: 41, Issue:4 Topics: Administration, Oral; Adult; Aged; Cross-Over Studies; Dopamine Agonists; Drug Administration Schedu	2000
Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 2. Findings on periodic leg movements, arousals and respiratory variables. Neuropsychobiology, 2000, Volume: 41, Issue:4 Topics: Adult; Aged; Arousal; Cross-Over Studies; Dopamine Agonists; Drug Administration Schedule; Electromy	2000

Article	Year
Prolonged penile erection in the absence of sexual stimulation following ropinirole use for restless legs syndrome. Sleep medicine, 2020, Volume: 68 Topics: Dopamine Agonists; Humans; Indoles; Male; Penile Erection; Restless Legs Syndrome	2020
Adherence and persistence to ropinirole, pramipexole, and gabapentin in patients with newly diagnosed restless legs syndrome. Sleep medicine, 2018, Volume: 44 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Analgesics; Dopamine Agonists; Female; Gabapentin; Huma	2018
Assessment of change in restless legs syndrome symptoms during the acute drug-withdrawal period. Sleep medicine, 2018, Volume: 52 Topics: Analgesics; Analgesics, Opioid; Dopamine Agonists; Electromyography; Female; Gabapentin; Humans; Ind	2018
Treatment-induced Delusions of Infestation Associated with Increased Brain Dopamine Levels. Acta dermato-venereologica, 2019, Mar-01, Volume: 99, Issue:3 Topics: Aged; Attention Deficit Disorder with Hyperactivity; Brain; Deep Brain Stimulation; Delusional Paras	2019
Major depression after withdrawing dopamine agonists in two patients with restless legs syndrome and impulse control disorders. Sleep medicine, 2013, Volume: 14, Issue:7 Topics: Aged, 80 and over; Benzothiazoles; Depressive Disorder, Major; Disruptive, Impulse Control, and Cond	2013
Decision-making, reward-seeking behaviors and dopamine agonist therapy in restless legs syndrome. Sleep, 2013, Oct-01, Volume: 36, Issue:10 Topics: Benzothiazoles; Case-Control Studies; Decision Making; Dopamine Agonists; Female; Gambling; Humans;	2013
Treatment of pediatric restless legs syndrome. Clinical pediatrics, 2014, Volume: 53, Issue:4 Topics: Adolescent; Amines; Analgesics; Anticonvulsants; Antioxidants; Benzothiazoles; Child; Child, Prescho	2014
A mixed treatment comparison of gabapentin enacarbil, pramipexole, ropinirole and rotigotine in moderate-to-severe restless legs syndrome. Current medical research and opinion, 2014, Volume: 30, Issue:11 Topics: Adult; Aged; Bayes Theorem; Benzothiazoles; Carbamates; Dopamine Agonists; Female; gamma-Aminobutyri	2014
Augmentation in restless legs syndrome patients in Korea. Sleep & breathing = Schlaf & Atmung, 2015, Volume: 19, Issue:2 Topics: Aged; Aged, 80 and over; Amines; Benzothiazoles; Cross-Sectional Studies; Cyclohexanecarboxylic Acid	2015
Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA internal medicine, 2014, Volume: 174, Issue:12 Topics: Adult; Aged; Aripiprazole; Benzothiazoles; Compulsive Behavior; Consumer Behavior; Dopamine Agonists	2014
Opioid-induced hyperalgesia and dopamine-induced augmentation in an intractable and refractory case of RLS. Sleep medicine, 2015, Volume: 16, Issue:10 Topics: Analgesics, Opioid; Dopamine Agonists; Drug Synergism; Female; Humans; Hyperalgesia; Indoles; Middle	2015
A method to switch from oral dopamine agonists to rotigotine in patients with restless legs syndrome and mild augmentation. Sleep medicine, 2016, Volume: 24 Topics: Administration, Oral; Aged; Benzothiazoles; Dopamine Agonists; Drug Synergism; Female; Humans; Indol	2016
Response to ropinirole in restless legs syndrome is independent of baseline serum ferritin. Journal of neurology, neurosurgery, and psychiatry, 2008, Volume: 79, Issue:8 Topics: Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Ferritins; Humans; Indoles	2008
Ropinirole-induced symptomatic sinus node dysfunction. Pacing and clinical electrophysiology : PACE, 2008, Volume: 31, Issue:8 Topics: Dopamine Agonists; Female; Humans; Indoles; Middle Aged; Restless Legs Syndrome; Syncope; Tachycardi	2008
Adverse effects of ropinirole-treated restless leg syndrome (RLS) during smoking cessation. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2008, Aug-15, Volume: 4, Issue:4 Topics: Dopamine Agonists; Dose-Response Relationship, Drug; Female; Humans; Indoles; Middle Aged; Restless	2008
Cost-effectiveness of licensed treatment options for restless legs syndrome in the UK and Sweden. Current medical research and opinion, 2008, Volume: 24, Issue:10 Topics: Benzothiazoles; Costs and Cost Analysis; Dopamine Agonists; Female; Humans; Indoles; Male; Markov Ch	2008
Punding in patients on dopamine agonists for restless leg syndrome. Movement disorders : official journal of the Movement Disorder Society, 2009, Jan-15, Volume: 24, Issue:1 Topics: Aged; Compulsive Behavior; Depression; Dopamine Agonists; Female; Gambling; Humans; Indoles; Middle	2009
Restless legs syndrome caused by quetiapine successfully treated with ropinirole in 2 patients with bipolar disorder. Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:6 Topics: Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Dopamine Agonists; Female; Humans; Indol	2008
Range of drugs associated with IFIS. Journal of cataract and refractive surgery, 2009, Volume: 35, Issue:1 Topics: Cataract Extraction; Dopamine Agonists; Humans; Indoles; Intraoperative Complications; Iris Diseases	2009
Restless leg syndrome, dopamine agonists and sleep attacks. Internal medicine journal, 2008, Volume: 38, Issue:11 Topics: Aged, 80 and over; Dopamine Agonists; Female; Humans; Indoles; Restless Legs Syndrome; Sleep Wake Di	2008
Unilateral RLS with predominantly ipsilateral PLMS and variable response to dopaminergic drugs: a variant of idiopathic RLS? European journal of neurology, 2009, Volume: 16, Issue:3 Topics: Aged; Dopamine Agents; Electromyography; Functional Laterality; Humans; Indoles; Levodopa; Magnetic	2009
[Impulse control disorder induced by the use of dopamine agonists]. Nederlands tijdschrift voor geneeskunde, 2009, Jan-17, Volume: 153, Issue:3 Topics: Benzothiazoles; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Humans; Indol	2009
Bilateral restless legs affecting a phantom limb, treated with dopamine agonists. Journal of neurology, neurosurgery, and psychiatry, 2009, Volume: 80, Issue:5 Topics: Amputation, Surgical; Dopamine Agonists; Humans; Indoles; Leg; Male; Middle Aged; Phantom Limb; Rest	2009
[Socioeconomic relevance of the idiopathic restless legs syndrome (RLS) in Germany: cost-of-illness study]. Medizinische Klinik (Munich, Germany : 1983), 2009, May-15, Volume: 104, Issue:5 Topics: Benzothiazoles; Delayed-Action Preparations; Dopamine Agents; Dopamine Agonists; Drug Costs; Financi	2009
An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease. The Annals of pharmacotherapy, 2009, Volume: 43, Issue:9 Topics: Aged; Aged, 80 and over; Databases, Factual; Dopamine Agonists; Female; Humans; Indoles; Male; Middl	2009
Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment. Journal of the neurological sciences, 2009, Dec-15, Volume: 287, Issue:1-2 Topics: Aged; Antiparkinson Agents; Benzothiazoles; Cognition Disorders; Comorbidity; Disability Evaluation;	2009
Comparative placebo-controlled polysomnographic and psychometric studies on the acute effects of gabapentin versus ropinirole in restless legs syndrome. Journal of neural transmission (Vienna, Austria : 1996), 2010, Volume: 117, Issue:4 Topics: Amines; Anti-Dyskinesia Agents; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric	2010
Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep, 2010, Volume: 33, Issue:1 Topics: Adult; Aged; Benzothiazoles; Case-Control Studies; Cross-Sectional Studies; Disruptive, Impulse Cont	2010
Liver toxicity possibly related with ropinirole use in the treatment of restless legs syndrome. European journal of neurology, 2011, Volume: 18, Issue:6 Topics: Aged; Chemical and Drug Induced Liver Injury; Dopamine Agonists; Female; Humans; Indoles; Jaundice,	2011
Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample. Sleep medicine, 2011, Volume: 12, Issue:5 Topics: Adult; Aged; Benzothiazoles; Cross-Sectional Studies; Dopamine Agonists; Female; Health Surveys; Hum	2011
Acupuncture for restless legs syndrome in patients previously treated with dopaminergic drugs. Acupuncture in medicine : journal of the British Medical Acupuncture Society, 2011, Volume: 29, Issue:3 Topics: Acupuncture Therapy; Adult; Aged; Aged, 80 and over; Benzothiazoles; Dopamine Agents; Humans; Indole	2011
[Pathological gambling induced by dopamine agonists]. Fortschritte der Neurologie-Psychiatrie, 2011, Volume: 79, Issue:8 Topics: Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Gambling; Humans; Indoles; Internat	2011
Breakthrough symptoms during the daytime in patients with restless legs syndrome (Willis-Ekbom disease). Sleep medicine, 2012, Volume: 13, Issue:2 Topics: Adult; Aged; Benzothiazoles; Circadian Rhythm; Clonazepam; Cross-Sectional Studies; Dopamine Agonist	2012
'You never told me I would turn into a gambler': a first person account of dopamine agonist--induced gambling addiction in a patient with restless legs syndrome. BMJ case reports, 2011, Aug-24, Volume: 2011 Topics: Cabergoline; Carbidopa; Cognitive Behavioral Therapy; Dopamine Agonists; Drug Combinations; Ergoline	2011
Dopamine agonist withdrawal syndrome in a patient with restless legs syndrome. Parkinsonism & related disorders, 2013, Volume: 19, Issue:2 Topics: Aged; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Female; Humans; Indoles	2013
Pregnancy outcome following use of levodopa, pramipexole, ropinirole, and rotigotine for restless legs syndrome during pregnancy: a case series. European journal of neurology, 2013, Volume: 20, Issue:9 Topics: Dopamine Agonists; Female; Humans; Indoles; Levodopa; Pregnancy; Pregnancy Complications; Pregnancy	2013
Severe restless legs syndrome presenting as intractable insomnia. Neurology, 2004, Apr-27, Volume: 62, Issue:8 Topics: Chronic Disease; Domperidone; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, D	2004
Ropinirole : a viewpoint by björn w. Walther. CNS drugs, 2004, Volume: 18, Issue:11 Topics: Dopamine Agonists; Humans; Indoles; Receptors, Dopamine; Restless Legs Syndrome	2004
Calming restless legs. Sleep, 2004, Aug-01, Volume: 27, Issue:5 Topics: Analgesics, Opioid; Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Humans; Indoles; Noctur	2004
Drug quiets restless legs syndrome. Health news (Waltham, Mass.), 2004, Volume: 10, Issue:12 Topics: Anti-Dyskinesia Agents; Dopamine Agonists; Humans; Indoles; Restless Legs Syndrome	2004
[Ropinirole treatment of restless legs]. Ugeskrift for laeger, 2005, Mar-14, Volume: 167, Issue:11 Topics: Aged; Antiparkinson Agents; Dopamine Agonists; Female; Follow-Up Studies; Humans; Indoles; Male; Mid	2005
Ropinirole in a child with attention-deficit hyperactivity disorder and restless legs syndrome. Pediatric neurology, 2005, Volume: 32, Issue:5 Topics: Attention Deficit Disorder with Hyperactivity; Child; Dopamine Agonists; Humans; Indoles; Male; Rest	2005
[Ropinirole in the treatment of restless legs]. Ugeskrift for laeger, 2005, Jun-06, Volume: 167, Issue:23 Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Indoles; Restless Legs Syndrome	2005
Ropinirole (Requip) for restless legs syndrome. The Medical letter on drugs and therapeutics, 2005, Aug-01, Volume: 47, Issue:1214 Topics: Dopamine Agonists; Dose-Response Relationship, Drug; Drug Approval; Drug Interactions; Female; Human	2005
Quelling the quivers caused by restless leg syndrome. The Johns Hopkins medical letter health after 50, 2005, Volume: 17, Issue:8 Topics: Dopamine Agonists; Humans; Indoles; Restless Legs Syndrome	2005
The reliability, validity and responsiveness of the Restless Legs Syndrome Quality of Life questionnaire (RLSQoL) in a trial population. Health and quality of life outcomes, 2005, Dec-05, Volume: 3 Topics: Adult; Aged; Dopamine Agonists; Double-Blind Method; Europe; Female; Humans; Indoles; Male; Middle A	2005
Psychosis related to ropinirole. The American journal of psychiatry, 2006, Volume: 163, Issue:3 Topics: Acute Disease; Adult; Dopamine Agonists; Female; Humans; Indoles; Psychoses, Substance-Induced; Rest	2006
GSK breached marketing code. BMJ (Clinical research ed.), 2006, Aug-19, Volume: 333, Issue:7564 Topics: Advertising; Codes of Ethics; Dopamine Agonists; Drug Industry; Humans; Indoles; Restless Legs Syndr	2006
[Dopamine agonists for treatment of restless leg syndrome]. Medizinische Monatsschrift fur Pharmazeuten, 2006, Volume: 29, Issue:8 Topics: Benzothiazoles; Clinical Trials as Topic; Dopamine Agonists; Humans; Indoles; Pramipexole; Restless	2006
Clinical studies with ropinirole in Parkinson's disease and RLS. Journal of neurology, 2006, Volume: 253 Suppl 4 Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Indoles; Parkinson Disease; Randomized Controlled T	2006
Efficacy and tolerability of ropinirole in patients with restless legs syndrome and a baseline IRLS total score > or = 24 points--data from the ropinirole clinical trial programme. Current medical research and opinion, 2006, Volume: 22, Issue:10 Topics: Adult; Aged; Dopamine Agonists; Female; Humans; Indoles; Male; Middle Aged; Randomized Controlled Tr	2006
Locomotion is increased in a11-lesioned mice with iron deprivation: a possible animal model for restless legs syndrome. Journal of neuropathology and experimental neurology, 2007, Volume: 66, Issue:5 Topics: Animals; Brain Injuries; Diencephalon; Disease Models, Animal; Dopamine Agonists; Indoles; Iron; Iro	2007
Effectiveness of ropinirole for RLS and depressive symptoms in an 11-year-old girl. Sleep medicine, 2009, Volume: 10, Issue:2 Topics: Child; Dopamine Agonists; Dysthymic Disorder; Female; Humans; Indoles; Restless Legs Syndrome; Treat	2009
Appropriate use of dopamine agonists and levodopa in restless legs syndrome in an ambulatory care setting. The Annals of pharmacotherapy, 2008, Volume: 42, Issue:5 Topics: Adult; Ambulatory Care; Dopamine Agonists; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Res	2008
Ropinirole for restless legs syndrome. Movement disorders : official journal of the Movement Disorder Society, 1999, Volume: 14, Issue:1 Topics: Adult; Aged; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Fema	1999

ropinirole and Restless Leg Syndrome